Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Brachial Plexopathy, CTCAE 5.0	NCIT_C146754	[A disorder characterized by regional paresthesia of the brachial plexus, marked discomfort and muscle weakness, and limited movement in the arm or hand.]
Anti-CEA/Anti-DTPA-In (F6-734) Bispecific Antibody	NCIT_C68927	[A bispecific monoclonal antibody (BsMAb) consisting of the Fab fragment of an anti-CEA monoclonal antibody (F6) coupled to the Fab fragment of an anti-DTPA-In monoclonal antibody (734) with potential radioimmunotherapeutic activity. In a two-step pretargeted radioimmunotherapeutic approach, this BsMAb, localizing to CEA-expressing tumor cells via the F6 Fab fragment, is introduced into patient first, followed by injection of indium 131-radiolabeled DTPA, which is recognized by the 734 Fab fragment of the BsMAb. Accordingly, a potentially lethal dose of indium 131 is delivered specifically to CEA-expressing tumor cells while minimizing radiotoxicity to normal tissues. CEA (carcinoembryonic antigen) is a tumor antigen overexpressed in many cancer types, including gastrointestinal, breast, non-small cell lung, and thyroid cancers. DTPA (diethylenetriaminepentaacetic acid) is a bivalent hapten.]
Necdin	NCIT_C107136	[Necdin (321 aa, ~36 kDa) is encoded by the human NDN gene. This protein plays a role in suppression of cell growth in postmitotic neurons.]
NDN Gene	NCIT_C107134	[This gene plays a role in cell cycle arrest.]
Therapeutic Estetrol	NCIT_C68928	[A synthetic steroid similar or identical to endogenous estetrol, a short-acting estrogen with both agonistic and antagonistic estrogen receptor activity. Administered orally, therapeutic estetrol binds to the estrogen receptor and as a selective estrogen receptor modulator (SERM) exhibits estrogen agonism in certain tissues and estrogen antagonism in others. Displaying weak estrogen activity in the uterus, estetrol acts as an estrogen antagonist in breast tissue. Produced solely by the human fetal liver, endogenous estetrol is the primary estrogen metabolite of estrogen biosynthesis in the human fetal liver.]
Kinome Response Profile	NCIT_C107137	[A protein expression profile to define and quantitate the activity and drug responsiveness of the expressed kinome.]
Proteomic Profile	NCIT_C97139	[A data set that both identifies all the proteins and quantifies the levels of their expression in a biological sample or specimen.]
Tyrosine Kinase Inhibitor XL228	NCIT_C68929	[A synthetic molecule that targets multiple tyrosine kinases with potential antineoplastic activity. Tyrosine kinase inhibitor XL228 binds to and inhibits the activities of multiple tyrosine kinases, such as the insulin-like growth factor 1 receptor (IGF1R), Src tyrosine kinase, and Bcr-Abl tyrosine kinase. Blockade of these kinases may result in the inhibition of tumor angiogenesis, cell proliferation, and metastasis. In addition, this agent may be a potent inhibitor of the T315I mutant form of the Abl protein, which is associated with the resistance of chronic myelogenous leukemia (CML) to other tyrosine kinase inhibitors. IGF1R and Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis. Bcr-Abl translocation leads to constitutive activation of ABL kinase and is commonly associated with Philadelphia-positive acute lymphocytic leukemia (ALL).]
17-Alpha-Hydroxypregnenolone	NCIT_C107138	[An endogenous steroid hormone synthesized by the hydroxylation of pregnenolone, which can act either as a neuroactive steroid or as a prohormone for progestogens, mineralocorticoids, glucocorticoids, androgens, estrogens, and the neuroactive steroids.]
Therapeutic Steroid Hormone	NCIT_C1636	[Synthetically made hormones possessing the steroid ring system; e.g., androgens, estrogens, and adrenocortical hormones.]
Kinome	NCIT_C107139	[The set of all kinases expressed in a cell or contained in a genome.]
Physical Examination	NCIT_C20989	[A systemic evaluation of the body and its functions using visual inspection, palpation, percussion and auscultation. The purpose is to determine the presence or absence of physical signs of disease or abnormality for an individual's health assessment.]
Phetharbital	NCIT_C29320	[A short-acting barbiturate derivative without hypnotic properties, Phetharbital (N-phenylbarbital) can be used as a sedative and anticonvulsant agent due to its mechanism of enhancing GABA (Gamma Amino Butyric Acid) transmission and inhibition of synaptic excitation. Phetharbital has generally been withdrawn from clinical use. (NCI04)]
Phosphate Buffer	NCIT_C29321	[A chemical reagent containing at least any one of the many phosphoric acid derivatives, usually in salt form. The phosphoric salt may be one of three types: strongly acid monometallic, neutral or mildly alkaline dimetallic, and strongly alkaline tri-metallic. Phosphate buffers are typically adjusted to maintain a certain pH or are "buffered" with other chemical compounds. Phosphate reagents are used in research laboratories, medicine or industry in various technical procedures. (NCI04)]
Phosphoramide Mustard	NCIT_C29322	[One of a number of chemically-related alkylating agents with antineoplastic properties. The prototype of this group of agents is cyclophosphamide. Most phosphoramide mustards are administered as prodrugs that undergo reductive activation in hypoxic environments to yield cytotoxic metabolites. These agents alkylate and crosslink DNA, resulting in inhibition of DNA replication. Phosphoramide mustards are also immunosuppressants, mutagens and teratogens. (NCI04)]
Nitrogen Mustard Compound	NCIT_C697	[A mustard agent containing nitrogen and chlorine atoms.]
Trefoil Factor 1	NCIT_C20986	[Encoded by human TFF1 Gene (Trefoil Family), 84-amino acid 9 kD (precursor) Trefoil Protein 1 (one trefoil domain) is expressed in stomach and duodenum. Trefoil proteins are stable secretory polypeptides expressed in gastrointestinal mucosa that have at least one trefoil motif (P-type domain), a 40-amino acid domain containing three conserved disulfides, and may protect the mucosa from insults, stabilize the mucus layer, and affect healing of the epithelium. The exact function has not been determined, but TFF1 may participate in gastrointestinal cell differentiation by delaying G1/S transition and reducing apoptosis. Strong expression is also found in the regenerative tissues surrounding ulcerous lesions of the gastrointestinal tract. (from Swiss-Prot P04155, OMIM 113710, and NCI)]
Abexinostat	NCIT_C68920	[An orally bioavailable hydroxamate-based pan-inhibitor of histone deacetylase (HDAC), with potential antineoplastic and radiosensitizing activities. Upon administration, abexinostat inhibits HDAC, resulting in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling; the selective transcription of tumor suppressor genes; and the tumor suppressor protein-mediated inhibition of tumor cell division and induction of tumor cell apoptosis. In addition, abexinostat decreases the expression of the DNA-repair protein RAD51, thereby reducing the RAD51 protein, preventing repair of DNA double-strand breaks and increasing sensitivity of tumor cells to DNA damaging agents. HDAC, upregulated in many tumor types, is an enzyme that is responsible for the deacetylation of chromatin histone proteins.]
Phsap	NCIT_C29323
Aldoxorubicin	NCIT_C68921	[A 6-maleimidocaproyl hydrazone derivative prodrug of the anthracycline antibiotic doxorubicin (DOXO-EMCH) with antineoplastic activity. Following intravenous administration, aldoxorubicin binds selectively to the cysteine-34 position of albumin via its maleimide moiety. Doxorubicin is released from the albumin carrier after cleavage of the acid-sensitive hydrazone linker within the acidic environment of tumors and, once located intracellularly, intercalates DNA, inhibits DNA synthesis, and induces apoptosis. Albumin tends to accumulate in solid tumors as a result of high metabolic turnover, rapid angiogenesis, hypervasculature, and impaired lymphatic drainage. Because of passive accumulation within tumors, this agent may improve the therapeutic effects of doxorubicin while minimizing systemic toxicity.]